Research
FDA-approved drug kills cancer cells in lab by disrupting cellular recycling
The Brief
- Researchers from VCU Massey Comprehensive Cancer Center showed that inhibiting glucosylceramide synthase (GCS) can kill cancer cells in the lab.
- The cell death occurs independently of changes in pro-death ceramide levels.
- The findings were recently published in a journal, per the source, and the work was demonstrated in laboratory cells.
Why it matters
The study points to a cell-death route that works through disrupting cellular recycling rather than through ceramide levels, which could inform future cancer drug research. Results so far come from lab experiments, not patients.
Who’s affected
- cancer researchers
- drug developers studying sphingolipid metabolism
- #cancer
- #cell biology
- #sphingolipids
- #drug research
- #lab study
Researchers from VCU Massey Comprehensive Cancer Center recently demonstrated that the inhibition of glucosylceramide synthase (GCS) can cause death in cancer cells that is independent of changes in pro-death ceramide levels. The findings, which were recently published in Cell…